NCT05939362 New Imaging Biomarkers Predictive of MA Progression
| NCT ID | NCT05939362 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Poitiers University Hospital |
| Condition | Alzheimer Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2023-10-02 |
| Primary Completion | 2027-10-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2023-10-02 with a primary completion date of 2027-10-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The pathophysiology of AD is complex. In addition to amyloid plaques and neurofibrillary degeneration, there is a metabolic alteration of the energy pathways, oxidative phosphorylation and glycolysis, which are involved in brain function. Several authors have shown a series of early metabolic dysregulations via an increase in phosphorylation at the origin of neuronal death. Ultra-high field imaging (7T MRI) may allow, with its better spatial resolution and advanced imaging techniques, to shed light on the mechanisms of progression of Alzheimer's disease. A Magnetic Resonance Spectroscopy (MRS) examination can be coupled to brain MRI without additional risk for the patient. Multinuclear 1H-31P metabolic imaging is a promising tool that can provide information on the metabolic evolutionary profile of AD. Thus, we propose a longitudinal study in patients with early-stage AD on 7T MRI-MRS.
Eligibility Criteria
Inclusion Criteria: * French-speaking patients aged 60 to 90 years, * Patient in the context of Alzheimer's disease \* for which imaging after MRI is prescribed as part of the usual diagnostic process, \*Alzheimer's disease is diagnosed by the doctor of the memory consultation and is defined by :Evidence of a storage disorder in verbal episodic memory at LR/RI defined by a sum of LR \< 17/48 and sum of RT \< 40/48 +/- Impairment of executive functions possible (BREF, TMT grefex, verbal fluencies) +/- Impairment of instrumental functions possible (Grémots noun naming, Rey's figure, Mahieux's Battery). * MMSE score ≥18, * Written informed consent after the patient has been informed, * Progressive decline for at least 6 months. Exclusion Criteria: --Partially or completely illiterate patient unable to read and write, * Patient with an absolute contraindication to 7T MRI * Severe psychiatric pathology not balanced, * Non-degenerative neurological disease (stroke, multiple sclerosis ...), * Patient with tumor or inflammatory pathology, or vascular leukopathy visualized in MRI (Fazekas score \> 3)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05939362 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, up to 90 Years, studying Alzheimer Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05939362 currently recruiting?
Yes, NCT05939362 is actively recruiting participants. Contact the research team at adrien.julian@chu-poitiers.fr for enrollment information.
Where is the NCT05939362 trial being conducted?
This trial is being conducted at Poitiers, France.
Who is sponsoring the NCT05939362 clinical trial?
NCT05939362 is sponsored by Poitiers University Hospital. The trial plans to enroll 80 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.